NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Adds Three New Patients to Phase IIA Study of MS1819-SD
AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning announced that, in partnership with French pharmaceutical firm Mayoly Spindler, it has enrolled three new patients to its phase IIA study of MS1819-SD for patients with exocrine pancreatic insufficiency caused by chronic pancreatitis. With these additions, the total number of patients enrolled in the trial is nine, and, with an enrollment target of 12-15 patients, AzurRx expects to complete enrollment in the first half of 2018. “We are very pleased that our existing clinical sites have recruited these new patients,”…







